Jefferies Raises Price Target on EZCORP (EZPW) to $6 Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Unusual 11 Mid-Day Movers 5/10: (CCXI) (CROX) (SODA) Higher; (EPRS) (NLNK) (JGW) Lower
May 10, 2016 12:50 PM EDTEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) 55.1% LOWER; announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference biologic Soliris®) for the potential treatment of ultra-rare blood disorders and BOW070 (tocilizumab; reference biologic Actemra) for the potential treatment of an uncommon lymphoproliferative disorder known as Castlemans disease.
ChemoCentryx, Inc. (Nasdaq: CCXI) 41.0% HIGHER; Vifor Pharmaand and... More
